BPCR vs. NBMI, ANIC, FWD, BRIG, ASIZ, MAVT, CTNA, DRUM, VLE, and STM
Should you be buying BioPharma Credit stock or one of its competitors? The main competitors of BioPharma Credit include NB Global Monthly Income Fund Ltd GBP (NBMI), Agronomics (ANIC), Forward Partners Group (FWD), BlackRock Income and Growth (BRIG), Aberforth Split Level Income ZDP 2024 (ASIZ), Momentum Multi-Asset Value Trust (MAVT), Catena Group (CTNA), Drumz (DRUM), Volvere (VLE), and STM Group (STM). These companies are all part of the "asset management" industry.
BioPharma Credit vs.
BioPharma Credit (LON:BPCR) and NB Global Monthly Income Fund Ltd GBP (LON:NBMI) are both small-cap financial services companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and community ranking.
BioPharma Credit received 84 more outperform votes than NB Global Monthly Income Fund Ltd GBP when rated by MarketBeat users.
In the previous week, BioPharma Credit's average media sentiment score of 0.00 equaled NB Global Monthly Income Fund Ltd GBP'saverage media sentiment score.
BioPharma Credit has higher revenue and earnings than NB Global Monthly Income Fund Ltd GBP. NB Global Monthly Income Fund Ltd GBP is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.
BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 823.5%. NB Global Monthly Income Fund Ltd GBP pays an annual dividend of GBX 9 per share. BioPharma Credit pays out 8,750.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. NB Global Monthly Income Fund Ltd GBP pays out 5,294.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
41.5% of BioPharma Credit shares are owned by institutional investors. Comparatively, 44.3% of NB Global Monthly Income Fund Ltd GBP shares are owned by institutional investors. 6.2% of BioPharma Credit shares are owned by company insiders. Comparatively, 0.2% of NB Global Monthly Income Fund Ltd GBP shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
BioPharma Credit has a net margin of 79.90% compared to NB Global Monthly Income Fund Ltd GBP's net margin of 0.00%. BioPharma Credit's return on equity of 8.10% beat NB Global Monthly Income Fund Ltd GBP's return on equity.
Summary
BioPharma Credit beats NB Global Monthly Income Fund Ltd GBP on 7 of the 11 factors compared between the two stocks.
Get BioPharma Credit News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioPharma Credit Competitors List
Related Companies and Tools
This page (LON:BPCR) was last updated on 1/22/2025 by MarketBeat.com Staff
Free BPCR Stock Alerts